Willy Simon joins Tiziana as non-executive director
November 27, 2015Research and Development Tiziana life sciences
Tiziana Life Sciences has appointed Willy Simon as a non-executive director who brings the benefit of a long and successful …
Pharma companies look to boost employee retention
November 27, 2015Medical Communications HR, India, Jobs, recruitment
Drug firms in India are devising novel ‘benching’ models to manage employee turnover. Attrition rates for pharma companies in India …
Mylan launches digital adherence programme for heart patients
November 27, 2015Medical Communications Canada, Mavik, Mylan, pharmacies, trandolapril
Mylan has launched an innovative digital medication adherence and engagement program for patients with high blood pressure. The digital programme, called …
Pfizer hires new lead for gene therapy research centre
November 26, 2015Medical Communications, Research and Development Pfizer
Pfizer has hired Professor Michael Linden to lead its new gene therapy research centre in London. Professor Michael Linden has …
Boehringer’s Praxbind reversal agent wins EU approval
November 26, 2015Medical Communications, Research and Development, Sales and Marketing
The European Commission has approved Boehringer Ingelheim’s Praxbind (idarucizumab)- a treatment to rapidly and specifically reverse the anticoagulant effects of …
Bayer takes on Actavis in ABPI code conduct breach
November 26, 2015Medical Communications, Sales and Marketing ABPI, Actavis, Bayer, PMCPA
The Prescription Medicines Code of Practice Authority (PMCPA) has ruled in favour of Bayer in a case brought against Actavis. …
Shkreli Daraprim price U-turn prompts renewed fury
November 26, 2015Medical Communications, Research and Development, Sales and Marketing
Turing CEO Martin Shkreli has sparked yet more criticism, after going back on a pledge to cut the price of …
Companies face mixed fortunes in ultra-orphan approvals
November 26, 2015Medical Communications, Research and Development BioMarin, Duchenne Muscular Dystrophy, FDA, Genzyme, NICE, ultra-orphan drugs
UK regulator NICE has recommended Vimizin, a drug for a very rare genetic disorder, after the manufacturer and NHS England …
GSK begins Phase III study of sirukumab in giant cell arteritis
November 26, 2015Business Services, Research and Development, Sales and Marketing GSK, Janssen
GSK today announced it has begun a Phase III study evaluating sirukumab, a human anti-interleukin (IL)-6 monoclonal antibody, for the …
Shire prepares new Baxalta bid
November 26, 2015Business Services, Sales and Marketing
Following rejection in an earlier bid, it has emerged that Shire is preparing a new takeover offer for US biotech …
Lilly cancer drug gets US approval
November 26, 2015NSCLC, Portrazza, lilly, lung cancer, necitumumab, non-small cell lung cancer, oncology
Eli Lilly has received FDA approval for its monoclonal antibody Portrazza, in combination with gemcitabine and cisplatin, for patients with …
Trump and Clinton hit out at Pfizer over tax inversion plan
November 25, 2015Sales and Marketing Allergan, Pfizer
Politicians on both sides of the US spectrum have criticised Pfizer over its $160 billion buyout of Allergan and its …
UK Spending Review: science budget protected, NHS gets £10 billion boost
November 25, 2015Research and Development
Feared 40% cuts to the UK’s science budget failed to materialise today, as Chancellor George Osborne announced the budget would …
Challenges in oncology R&D – part 2
November 25, 2015Manufacturing and Production, Research and Development R&D, Takeda, oncology
Pharmafile put questions on the challenges pharma companies face when working in oncology R&D to Dixie-Lee Esseltine, vice president of …
BMS and Medicines Patent Pool collaborate to increase Hep C medicine access
November 25, 2015Manufacturing and Production, Research and Development Bristol-Myers Squibb, Medicines Patent Pool, daclatasvir, daklinza, hepatitis C
The Medicines Patent Pool (MPP) has announced its first licence for a hepatitis C medicine, signing an agreement with Bristol-Myers …
Teva and Heptares enter $400m agreement for small-molecule migraine treatment
November 25, 2015Research and Development Heptares, Teva, collaboration, migraine
Teva Pharmaceuticals and Heptares Therapeutics have signed a licensing and drug-discovery agreement for Teva to gain exclusive global rights to …
UK commits £150 million to new Dementia Research Institute
November 25, 2015Research and Development dementia. R&D
The UK government has launched plans for a new £150 million dementia research institute that it says will drive a …
Bristol-Myers Squibb in new oncology collaboration
November 25, 2015Research and Development Bristol-Myers Squibb, collaboration, immuno-oncology, investment, venture capital
Bristol-Myers Squibb and European healthcare fund Life Sciences Partners are forming a strategic collaboration to identify breakthrough technologies. The companies …
PlaqueTec appoints Dr Nick West as CMO
November 24, 2015Research and Development PlaqueTec
PlaqueTec has appointed Dr Nick West as its new chief medical officer. Dr West is a research-active clinician with extensive …
FDA approves BMS’s Opdivo for renal cell carcinoma
November 24, 2015Research and Development
The FDA has approved Bristol Myers Squibb’s immunotherapy Opdivo for the treatment of patients with advanced renal cell carcinoma (RCC). …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
